Article
Oncology
Yuxiang Ma, Wenfeng Fang, Hongyun Zhao, Sai Praneeth Bathena, Amol Tendolkar, Jennifer Sheng, Li Zhang
Summary: The study found that the overall safety profiles of ipilimumab in Chinese patients with solid tumors were consistent with previous U.S. studies, with lower systemic exposures in Chinese patients but overlapping serum concentrations between Chinese and U.S. populations. The drug was well tolerated in Chinese patients, without new safety concerns.
Article
Oncology
Yang Luo, Ying Cheng, Chunjiao Wu, Hui Ye, Naihan Chen, Fan Zhang, Hua Wei, Binghe Xu
Summary: This phase 1 study examined the pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. The results demonstrated that the pharmacokinetic profile of talazoparib in Chinese patients was similar to that in Western populations, and the treatment was well-tolerated.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Xu Liang, Junli Xue, Xiaoxiao Ge, Jin Li, Huiping Li, Liqiong Xue, Lijun Di, Wenbo Tang, Guohong Song, Qun Li, Hanfang Jiang, Wei Zhao, Fengjuan Lin, Bin Shao, Xiugao Yang, Zhufeng Wu, Tianyi Zhang, Chenchen Wang, Ye Guo
Summary: Bone metastases are common complications of solid tumors. This study found that JMT103 is effective in treating bone metastases from solid tumors and is well tolerated by patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Junning Cao, Hongqian Guo, Dongmei Ji, Weina Shen, Shun Zhang, Chih-Yi Hsieh, Sui Xiong Cai, Ye Edward Tian, Cong Xu, Pin Zhang, Binghe Xu
Summary: This phase I study investigated the pharmacokinetics, safety, tolerability, and preliminary antitumor activity of Senaparib in Chinese patients with advanced solid tumors. The results showed that Senaparib was well tolerated and demonstrated promising antitumor activity in these patients. The recommended phase II dose was identified as 100 mg once daily.
Article
Infectious Diseases
Na Liu, Xiaohong Wang, Jixiang Zhu, Sumit Basu, Yudong Wei, Bei Yan, Hui Wang, Francheska Colon-Gonzalez, Hwa-Ping Feng, Fang Sun, Haiyan Li, Yanqiao Zang
Summary: This study evaluated the pharmacokinetics, safety, and tolerability of C/T in 12 healthy Chinese participants. The results showed that the pharmacokinetics and safety/tolerability of C/T in healthy Chinese participants were comparable to that in other populations, supporting the use of C/T for the treatment of Chinese patients.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Clinical Neurology
Beibei Liang, Jin Wang, Guanxuanzi Zhang, Rui Wang, Yun Cai
Summary: This study aimed to assess the safety, tolerability, and pharmacokinetics of SYHA1402 in healthy Chinese subjects. The results showed that SYHA1402 was well tolerated and safe when administered as a single dose in the range of 25-800 mg, and over 50% of the unchanged drug was excreted in urine.
NEUROLOGY AND THERAPY
(2023)
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the efficacy and tolerability of avelumab in Chinese patients. The results showed that avelumab at different doses can stabilize the disease and have partial responses in some patients' tumors.
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the safety and pharmacokinetics of avelumab in Chinese patients with advanced solid tumors. The results were consistent with previous global studies, showing some therapeutic effects in Chinese patients.
Article
Oncology
Justin A. Chen, Jasmine C. Huynh, Chun-Yi Wu, Ai-Ming Yu, Karen Matsukuma, Thomas J. Semrad, David R. Gandara, Tianhong Li, Jonathan W. Riess, Kit Tam, Philip C. Mack, Anthony Martinez, Nichole Mahaffey, Karen L. Kelly, Edward J. Kim
Summary: The combination therapy of alisertib and gemcitabine shows potential for disease control in heavily pre-treated tumors, but gastrointestinal and hematologic toxicity is apparent.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Microbiology
Xiaohong Wang, Na Liu, Yudong Wei, Shuang Zhang, Haiyan Li, Bei Yan, Munjal Patel, Hui Wang, Keith E. Boundy, Francheska Colon-Gonzalez, Yanqiao Zang, Xumin Zhao
Summary: This study evaluated the pharmacokinetics, safety, and tolerability of relebactam/imipenem/cilastatin in 12 healthy Chinese participants. The results showed that the drug behaved similarly in Chinese participants compared to other ethnicities, supporting its use in Chinese patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Yulia Vugmeyster, Ana-Marija Grisic, Brigitte Brockhaus, Peter Rueckert, Mary Ruisi, Haiqing Dai, Akash Khandelwal
Summary: The study evaluated the pharmacokinetics of avelumab in pediatric patients with solid tumors. The optimal dose for pediatric patients was determined based on exposure matching with adult data, recommending a lower dose for younger or lighter patients and the adult flat dose for older or heavier patients. This information can inform future avelumab studies, including combination therapies.
CLINICAL PHARMACOKINETICS
(2022)
Article
Plant Sciences
Ruihua Dong, Lijun Li, Hongzhi Gao, Kun Lou, Hongmei Luo, Sheng Hao, Jing Yuan, Zeyuan Liu
Summary: Scutellaria baicalensis (Huang-Qin in Chinese) is an herb high in flavonoids, with baicalein being the most abundant flavonoid. This study evaluated the safety and pharmacokinetic characteristics of baicalein in vivo, showing that baicalein tablets within the studied dose range were safe and well-tolerated in healthy Chinese subjects. Further research is needed to assess safety and efficacy in target patients.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Hui-Jen Tsai, Her-Shyong Shiah, Jang-Yang Chang, Wu-Chou Su, Nai-Jung Chiang, Li-Tzong Chen
Summary: This study determined the maximal tolerated dose (MTD) of S-1 when combined with sorafenib for refractory solid tumors to be 30 mg/m(2) bid. Some patients achieved durable partial response or stable disease with this regimen. Further phase II studies are warranted to evaluate the efficacy of this combination in advanced pNET and colon cancer.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Dan Liu, Lei Liu, Lin Shen, Tomoki Kubota, Takuya Suzuki, Hiroki Ikezawa, Sari Shiba, Yuxian Bai
Summary: This study assessed the pharmacokinetics of once-daily oral lenvatinib in Chinese patients and found that the data were consistent with multinational trials, supporting the usage of the 24-mg dose.
Article
Microbiology
Yuran Cao, Xiaojie Wu, Zhiqiang Wang, Yuxian Huang, Junzhen Wu, Guoying Cao, Jicheng Yu, Jingjing Wang, Haijing Yang, Wenhong Zhang, Jing Zhang
Summary: Holybuvir, a novel pangenotypic hepatitis C virus NS5B inhibitor, was evaluated for its pharmacokinetics, safety, and tolerability in healthy Chinese subjects. The study showed that single oral administration of holybuvir up to 1,200 mg was well tolerated and rapidly absorbed and metabolized in the human body. PK analysis indicated non-dose proportional increase in C-max and AUC after single-dose administration. Although high-fat meals affected the PK of holybuvir and its metabolites, further confirmation of the clinical significance is required. Accumulation of metabolites was observed with multiple-dose administration, supporting the further development of holybuvir for HCV patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Oncology
Hong-xia Tian, Zhi-hong Chen, Guang-Ling Jie, Zhen Wang, Hong-hong Yan, Si-pei Wu, Shui-lian Zhang, Dan-xia Lu, Xu-chao Zhang, Yi-long Wu
Summary: This study investigated the characteristics and prognostic features of the NF1 gene in EGFR mutant lung cancer patients. The results showed that NF1 mutations were enriched in older, male, and smoking patients, and were mutually exclusive with TP53, BRAF, and RASA1 mutations. TP53 mutation worsened the prognosis in cases of NF1 mutant or EGFR/NF1 co-mutant lung adenocarcinomas. NF1 mutations were not associated with overall survival in lung adenocarcinoma patients, but NF1/EGFR co-mutation patients had a longer overall survival than those with a single mutation of either gene. Furthermore, NF1 mutations significantly prolonged overall survival in EGFR mutant/TP53 wild-type patients but not in patients with EGFR/TP53 co-mutations.
Article
Oncology
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis
Summary: This study reports the final analysis from ASTRIS, the largest real-world study of osimertinib in patients with advanced/metastatic EGFR T790M NSCLC. The results demonstrate the clinical benefit and safety of osimertinib in this patient population.
Article
Oncology
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Summary: The study demonstrates that adjuvant osimertinib provides a prolonged disease-free survival (DFS) benefit, reduces the risk of recurrence, improves central nervous system (CNS) DFS, and has a consistent safety profile in resected EGFR-mutated NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Guang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, Hao Sun, Song-Rong Wang, Si-Yang Maggie Liu, Kai Yin, Zhi-Hong Chen, Hong-Xia Tian, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Qing Zhou, Catherine C. L. Wong, Yi-Long Wu
Summary: This study explores the clinical utility of plasma proteomics-derived biomarkers for MET-dysregulated NSCLC patients treated with MET inhibitors. Mass spectrometry analysis of longitudinal plasma samples revealed that the peripheral plasma proteomic characteristics were associated with treatment outcomes. A four-protein signature (MYH9, GNB1, ALOX12B, and HSD17B4) was identified as a high-accuracy predictor of response and progression-free survival in patients treated with MET inhibitors.
Article
Oncology
Yan Sun, Liang Zhu, Pian Liu, Huan Zhang, Feng Guo, Xin Jin
Summary: In this study, researchers found that the upregulation of palmitoyl acyltransferase ZDHHC2 is associated with TKI resistance in ccRCC. ZDHHC2 mediates AGK S-palmitoylation to activate the PI3K-AKT-mTOR signaling pathway, which modulates sunitinib sensitivity. These findings suggest that targeting ZDHHC2 may improve the efficacy of sunitinib in treating ccRCC.
Article
Multidisciplinary Sciences
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Summary: The third-generation EGFR tyrosine kinase inhibitor osimertinib improves progression-free survival compared to platinum-doublet chemotherapy in patients with advanced NSCLC carrying EGFR T790M mutation. In this study, the authors used next-generation sequencing to evaluate the potential mechanisms of acquired resistance to osimertinib in patients from the AURA3 trial. Some patients had undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation.
NATURE COMMUNICATIONS
(2023)
Letter
Oncology
Ling Peng, Yawen Bin, Peng Ding, Lingjuan Chen, Hao Zeng, Zelong Xu, Liyan Ji, Xuan Gao, Pian Liu, Ye Wang, Sheng Zhang, Zhongxing Liao, Xuefeng Xia, Ruiguang Zhang, Fan Tong, Xiaorong Dong
CANCER COMMUNICATIONS
(2023)
Letter
Oncology
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Summary: This study identified specific TCR sequences that can predict prognosis and favorable outcomes in EGFR-mutant NSCLC patients treated with adjuvant EGFR-TKI.
BIOMARKER RESEARCH
(2023)
Article
Oncology
Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid Mckeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Summary: Plasma EGFRm analysis can predict the efficacy in EGFRm advanced NSCLC, especially when performed at around 3 weeks of treatment to predict the progression-free survival.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Lixin He, Jinxin Chen, Pinwei Deng, Shumei Huang, Pian Liu, Chanjuan Wang, Xinjian Huang, Yue Li, Boyu Chen, Dongni Shi, Yunyun Xiao, Xiangfu Chen, Ying Ouyang, Libing Song, Chuyong Lin
Summary: Cyst(e)ine plays a crucial role in the synthesis of glutathione and its storage in lysosomes helps cancer cells maintain redox homeostasis. Breast cancer cells upregulate MFSD12 to increase lysosomal cyst(e)ine storage, which is released to maintain GSH levels and buffer oxidative stress. mTORC1 regulates MFSD12 by phosphorylating residue T254, and this switch modulates lysosomal cyst(e)ine levels in response to oxidative stress, enhancing cell fitness. MFSD12 mutation inhibits its function and suppresses tumor progression, while its overexpression correlates with poor chemotherapy response and prognosis in breast cancer patients.
Article
Oncology
Haiqin Wang, Haohui Wang, Jiajing Chen, Pian Liu, Xiaoxiong Xiao
Summary: Studies have found that FAM111B is highly expressed in esophageal cancer tissues and promotes the progression of esophageal cancer cells by binding to GSDMA. The FAM111B/GSDMA axis also regulates the sensitivity of esophageal cancer to cisplatin. This discovery reveals a novel pathway that plays a significant role in esophageal cancer tumorigenesis and chemosensitivity.
Review
Oncology
Yang-Si Li, Guang-Ling Jie, Yi-Long Wu
Summary: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for non-small-cell lung cancer (NSCLC) with active EGFR mutations. However, resistance to EGFR-TKIs eventually develops, necessitating alternative treatment options for extensively pretreated patients with EGFR-mutant NSCLC. New agents, such as fourth-generation EGFR-TKIs, combination therapy with targeted drugs, and antibody-drug conjugates, have shown promising efficacy in clinical trials for this patient population. This review summarizes the current efforts in managing extensively pretreated patients with EGFR-mutant NSCLC.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Muwen Yang, Yue Li, Lingzhi Kong, Shumei Huang, Lixin He, Pian Liu, Shuang Mo, Xiuqing Lu, Xi Lin, Yunyun Xiao, Dongni Shi, Xinjian Huang, Boyu Chen, Xiangfu Chen, Ying Ouyang, Jun Li, Chuyong Lin, Libing Song
Summary: HER2-targeted therapy is the main treatment for HER2+ breast cancer, but HER2 shedding reduces the effectiveness of anti-HER2 therapy. This study found that upregulation of DPAGT1 sustains HER2 shedding and confers trastuzumab resistance. Inhibition of DPAGT1 in combination with trastuzumab treatment can block HER2 signaling and reverse resistance.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, Yukyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric
Summary: Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile. The results of this study are of great importance for improving patient outcomes and guiding clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Roy S. Herbst, Yi-Long Wu, Masahiro Tsuboi
JOURNAL OF CLINICAL ONCOLOGY
(2023)